LOS ANGELES, April 26, 2017 /PRNewswire/ -- Capricor
Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology
company developing first-in-class biological therapies for cardiac
and other medical conditions, today announced that Linda Marbán,
Ph.D., president and chief executive officer, is scheduled to
present at the Alliance for Regenerative Medicine's 5th
Annual Cell & Gene Therapy Investor Day on April 27, 2017 at The State Room in Boston, Massachusetts. The presentation will
begin at approximately 9:40 a.m. eastern
time and a live webcast of the event will be available at
www.arminvestorday.com/webcast/.
About Capricor Therapeutics
Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a clinical-stage
biotechnology company developing first-in-class biological
therapies for cardiac and other medical conditions. Capricor's lead
candidate, CAP-1002, is a cell-based candidate currently in
clinical development for the treatment of Duchenne muscular
dystrophy, myocardial infarction (heart attack), and heart failure.
Capricor is exploring the potential of CAP-2003, a cell-free,
exosome-based candidate, to treat a variety of disorders. For more
information, visit www.capricor.com.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release regarding the efficacy,
safety, and intended utilization of Capricor's product candidates;
the initiation, conduct, size, timing and results of discovery
efforts and clinical trials; the pace of enrollment of clinical
trials; plans regarding regulatory filings, future research and
clinical trials; plans regarding current and future collaborative
activities and the ownership of commercial rights; scope, duration,
validity and enforceability of intellectual property rights; future
royalty streams, expectations with respect to the expected use of
proceeds from the recently completed offerings and the anticipated
effects of the offerings, and any other statements about Capricor's
management team's future expectations, beliefs, goals, plans or
prospects constitute forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. Any
statements that are not statements of historical fact (including
statements containing the words "believes," "plans," "could,"
"anticipates," "expects," "estimates," "should," "target," "will,"
"would" and similar expressions) should also be considered to be
forward-looking statements. There are a number of important factors
that could cause actual results or events to differ materially from
those indicated by such forward-looking statements. More
information about these and other risks that may impact Capricor's
business is set forth in Capricor's Annual Report on Form 10-K for
the year ended December 31, 2016, as
filed with the Securities and Exchange Commission on March 16, 2017, and in its Registration Statement
on Form S-3, as filed with the Securities and Exchange Commission
on September 28, 2015, together with
prospectus supplements thereto. All forward-looking statements in
this press release are based on information available to Capricor
as of the date hereof, and Capricor assumes no obligation to update
these forward-looking statements.
CAP-1002 is an Investigational New Drug and is not approved
for any indications. Capricor's exosomes technology, including
CAP-2003, has not yet been approved for clinical
investigation.
For more information, please contact:
Corporate
Capricor Therapeutics, Inc.
AJ Bergmann, Vice President of Finance
+1-310-358-3200
abergmann@capricor.com
Investor Relations
Argot Partners
Kimberly Minarovich
+1-212-600-1902
kimberly@argotpartners.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/capricor-therapeutics-to-present-at-the-alliance-for-regenerative-medicines-cell--gene-therapy-investor-day-300445808.html
SOURCE Capricor Therapeutics, Inc.